Published within
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
New Phase III data show that investigational candidate IPX066 offers a significant improvement over carbidopa-levodopa plus entacapone in the treatment of Parkinson's disease. IPX066's strength lies in its reduced "off time" compared to immediate-release formulations. However, an appropriate pricing strategy will be critical for the drug's commercial success.
Published By Datamonitor
|
15 Aug 2011 |
|
CommentWire
|
With global sales of over $300m in 2010, and sales potentially exceeding $3bn by 2015, biosimilars have become a key focus for drugmakers. Already a number of biosimilars have launched in developed markets, with hundreds of copy-biologics available in the emerging markets. Furthermore, Datamonitor has identified approximately 200 pipeline candidates, reflecting the growth potential of this market.
Published By Datamonitor
|
15 Dec 2011 |
|
Expert View
|
Following the FDA's rejection of Qutenza for the management of HIV-related pain, the product's potential in the neuropathic pain market will remain limited to postherpetic neuralgia. NeurogesX intends to shift its focus to the development of NGX-1998, a more user-friendly liquid formulation of the drug. However, current topical pipeline agents will provide fierce competition.
Published By Datamonitor
|
13 Mar 2012 |
|
Expert View
|
New data presented at the World Vaccines Congress demonstrate that BiondVax's developmental influenza vaccine can also act as a booster to existing seasonal influenza vaccines in elderly patients. A vaccine with increased efficacy in the elderly is one of the largest unmet needs in influenza prevention, although the need for patients to take multiple vaccinations may hinder its success.
Published By Datamonitor
|
13 Apr 2012 |
|
CommentWire
|
The FDA's ODAC has recommended Kyprolis, the multiple myeloma treatment from Proteolix and Onyx Pharmaceuticals, despite ongoing cardiac and hepatic toxicity concerns. If approved, the drug will threaten Velcade's share of the myeloma market and could pose a threat to Johnson & Johnson's future revenues.
Published By Datamonitor
|
21 Jun 2012 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.